8-K
filed July 17, 2023, 7:59 PM ET
ticker PDSB
CIK 0001472091
other material
confidence high
sentiment neutral
materiality 0.50
PDS Biotechnology shareholders approve 2.4M share increase in equity plan, reelect directors
PDS Biotechnology Corp
- Stockholders approved Third Amended Restated 2014 Equity Plan, increasing authorized shares from 4,165,535 to 6,565,535.
- Elected Class B directors Kamil Ali-Jackson and Ilian Iliev; each received >5M votes for, 10M+ broker non-votes.
- Ratified KPMG as independent auditor for FY2023 with 17.2M votes for, 259K against.
- Non-binding advisory vote on executive compensation approved: 6.0M for, 1.4M against, 10.1M broker non-votes.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PDS Biotechnology Corp shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PDS Biotechnology Corp shareholders approved Approval of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
The Company’s stockholders voted to approve the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PDS Biotechnology Corp shareholders approved Ratification of Appointment of KPMG US LLP at the 2023-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-31
Exact text from the filing
The Company’s stockholders ratified the appointment of KPMG US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PDS Biotechnology Corp shareholders approved Election of Class B Directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
The Company’s stockholders elected the following directors to serve as Class B directors until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.